Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
LetterLetter to the Editor

Comments on “Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome”

Jolanta Skarbaliene, Bjarne Due Larsen, Mark Berner-Hansen and Adam Steensberg
Journal of Pharmacology and Experimental Therapeutics June 2021, 377 (3) 369; DOI: https://doi.org/10.1124/jpet.120.000426
Jolanta Skarbaliene
Research and Development, Zealand Pharma A/S, Sydmarken 11, 2860 Søborg, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bjarne Due Larsen
Research and Development, Zealand Pharma A/S, Sydmarken 11, 2860 Søborg, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Berner-Hansen
Research and Development, Zealand Pharma A/S, Sydmarken 11, 2860 Søborg, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam Steensberg
Research and Development, Zealand Pharma A/S, Sydmarken 11, 2860 Søborg, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

This article has a correction. Please see:

  • Correction to “Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome” - June 01, 2021

We read with interest the publication entitled “Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome” (Hargrove et al., 2020). The authors investigated the pharmacology and pharmacokinetic (PK) properties of apraglutide, comparing it directly with teduglutide and glepaglutide. The authors concluded that apraglutide showed a greater ability to stimulate growth of the small intestine in rats relative to teduglutide and glepaglutide when directly compared at two doses (30 and 300 nmol/kg; Fig. 5).

Given that the study results may influence future basic research, drug development programs and eventually clinical practice, we consider it important to point out some key errors relating to the synthesis and formulation of glepaglutide used by Hargrove et al. that may invalidate a number of results and conclusions in the paper.

The authors claim that glepaglutide was identified from a published patent application (WO06117565A2) and described the amino acid sequence of the peptide as well as its counter ion used in their studies (Hargrove et al. (2020), Table 1). The amino acid sequence of glepaglutide is however not correct.

Hargrove et al. prepared all peptides as trifluoroacetic acid (TFA) salts, whereas we have developed glepaglutide as an acetate salt. The salt identity of glepaglutide is of relevance for the quality of the experimental work, data generated, and validity of conclusions drawn in the paper. In addition, for the pharmacodynamic (PD) studies, apraglutide, teduglutide and low doses (30 nmol/kg) of glepaglutide were dissolved in 25 mM phosphate buffer at pH 7.4, while the high dose of glepaglutide (300 nmol/kg) was dissolved in sterile water in contrast to the other solutions.

Dissolving a TFA salt of any peptide, including glepaglutide, in an unbuffered solution will result in a solution with very low pH. This may impact solubility and stability of glepaglutide, thus yielding potentially misleading results in PK and PD studies. Furthermore, by using a TFA salt in an unbuffered solution, we suspect that distribution from the subcutaneous injection depot is negatively impacted due to the very low pH. Therefore, comparison of the data obtained for glepaglutide TFA salt in sterile water to the other compounds in the paper is misleading.

Given the errors in the Hargrove et al. (2020) paper, we conclude that the peptide used in the study cannot be glepaglutide. This, together with the formulation issues described above, leads us to conclude that any representations of in vivo data describing the comparison of apraglutide to glepaglutide may not be valid. The conclusion that “apraglutide has greater ability to stimulate small intestine growth relative to glepaglutide “is therefore misleading.

  • Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics

Reference

  1. ↵
    1. Hargrove DM,
    2. Alagarsamy S,
    3. Croston G,
    4. Laporte R,
    5. Qi S,
    6. Srinivasan K,
    7. Sueiras-Diaz J,
    8. Wiśniewski K,
    9. Hartwig J,
    10. Lu M, et al.
    (2020) Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome. J Pharmacol Exp Ther 373:193–203.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 377 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 377, Issue 3
1 Jun 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Comments on “Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome”
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
LetterLetter to the Editor

Comments on “Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome”

Jolanta Skarbaliene, Bjarne Due Larsen, Mark Berner-Hansen and Adam Steensberg
Journal of Pharmacology and Experimental Therapeutics June 1, 2021, 377 (3) 369; DOI: https://doi.org/10.1124/jpet.120.000426

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
LetterLetter to the Editor

Comments on “Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome”

Jolanta Skarbaliene, Bjarne Due Larsen, Mark Berner-Hansen and Adam Steensberg
Journal of Pharmacology and Experimental Therapeutics June 1, 2021, 377 (3) 369; DOI: https://doi.org/10.1124/jpet.120.000426
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Reference
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Letter to the Editor
  • Vidarabine and AC5
Show more Letter to the Editor

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics